

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B-PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 1

Complete if Known

Application Number	09/870,089
Filing Date	May 30, 2001
First Named Inventor	Charles A. NICOLETTE
Art Unit	1614
Examiner Name	Not Yet Assigned
Attorney Docket No.	GZ 2099.00

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher city and/or country where published	T ²
JC42	1	TSUJIMOTO, A. et al. "Isolation of cDNA-Binding Proteins Which Specifically Bind to a tax-Responsive Enhancer Element in the Long Terminal Repeat of Human T-Cell Leukemia Virus Type I" (1991) J. Vir. 65(3):1420-1426	
	2	KARPINSKI, B.A. et al., "Molecular Cloning of Human Creb-2: An ATF/CREB Transcription Factor that can Negatively Regulate Transcription from the camp Response Element" P.N.A.S. (1992) 89:4820-4824	
	3	EMBL Online, Accession No. M86842	
	4		
	5		
	6		
	7		
	8		
	9		
	10		
	11		
	12		
	13		
	14		
	15		
	16		
	17		
	18		
	19		
	20		
	21		
	22		
	23		
	24		
	25		
	26		
	27		

RECEIVED

JUL 26 2002

TECH CENTER 1600/2900

Examiner's
Signature

Date

Considered: 12/23/03

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

† Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

COPY OF PAPERS
ORIGINALLY FILED

14B

#14

PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known

Substitute for form 1449A-PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 1

Applicati n Numb r	09/870,089
Filing Date	May 30, 2001
First Named Inventor	Charles A. NICOLETTE
Art Unit	1614
Examiner Name	Not Yet Assigned
Attorney Docket No.	GZ 2099.00

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number Number - Kind Code ² (if known)	Publication Date MM-DD-YY	Name of Patentee or Application of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
gm	1	US-5,688,657	11-18-97	Tsang, et al.	
	2				
	3				
	4				
	5				
	6				
	7				
	8				
	9				
	10				

RECEIVED

RECEIVED

AUG 14 2002

JUL 26 2002

TECH CENTER 1600/2900

TECH CENTER 1600/2900

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)	Publication Date MM-DD-YY	Name of Patentee or Application of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
	11					
	12					
	13					
	14					
	15					
	16					

Examiner's
SignatureDate
Considered


12/23/03

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

† Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

**COPY OF PAPERS
ORIGINALLY FILED**



+

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known			
		Application Number	09/870,089		
		Filing Date	May 30, 2001		
		First Named Inventor	Nicolette		
		Art Unit	1614		
		Examiner Name	Unassigned		
Sheet	1	of	1	Attorney Docket Number	GZ 2099.00

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), data, page(s), volume-issue number(s), publisher city and/or country where published	T ²
Gu	1	Tsujimoto, A., et al.: "Isolation of CDNAS for DNA-Binding Proteins which Specifically Bind to a Tax-Responsive Enhancer Element in the Long Terminal Repeat of Human T-Cell Leukemia Virus Type I" Journal of Virology, New York, US, Vol. 65, No. 3, March 1991 (1991-03), pages 1420-1426.	
Gu	2	Mielnicki, et al.: "Mutated Atf4 Suppresses c-Ha-ras Oncogene Transcript Levels and Cellular Transformation in NIH3T3 Fibroblasts" Biochemical and Biophysical Research Communications, Vol. 228, 1996, pages 586-595.	
	3		
	4		
	5		
	6		
	7		
	8		
	9		
	10		
	11		
	12		
	13		
	14		
	15		
	16		
	17		
	18		
	19		
	20		
	21		
	22		
	23		
	24		
	25		
	26		


RECEIVED
FEB 26 2003
TECH CENTER 1600/2900

Examiner's Signature	<i>A. L. [Signature]</i>	Date Considered	12/23/03
----------------------	--------------------------	-----------------	----------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

+ Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.



PTO/SB/08A (10-01)
Approved for use through 10/31/2002. OMB 0851-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 1

Complete if Known

Application Number	09/810,089
Filing Date	May 30, 2001
First Named Inventor	Nicolette
Art Unit	1614
Examiner Name	Unassigned
Attorney Docket Number	GZ 2099.00

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YY	Name of Patentee or Application of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
	1	US-			
	2	US-			
	3	US-			
	4	US-			
	5	US-			
	6	US-			
	7	US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YY	Name of Patentee or Application of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ³
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
gm	8	WO 99/54353-A	10-28-99	Schmitt	Pgs. 1-4; Seq. 48	
	9	WO 00/55174-A	09-21-00	Human Genome Sciences	Page 3	
	10	WO 01/57271-A	08-09-01	Wensheng	Page 6; Seq. 12165	
	11	WO 01/92306-A	12-06-01	Genzyme	entire doc.	
	12					
	13					
	14					
	15					
	16					
	17					
	18					
	19					
	20					
	21					

Examiner's
Signature


Date
Considered

12/23/03


* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

+ Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

PTO/SB/08 (2/92)
Sheet 1 of 4

Form PTO-1449		Docket No. 126881209900		Appl. No. 09/870,089 <i>SM</i>			
INFORMATION DISCLOSURE STATEMENT		Applicant(s) Charles A. NICOLETTE					
(use several sheets if necessary)		Filing Date: May 30, 2001		Group Art Unit: Unassigned			
U.S. PATENT DOCUMENTS							
Examiner Initials	Ref. No.	Date	Document No.	Name	Class Subclass Filing Date (if appropriate)		
<i>GAX</i> ↓ <i>V</i>	1.	07/28/87	4,683,195	Mullis et al.	<i>TC 1700</i>		
	2.	07/28/87	4,683,202	Mullis			
	3.	06/28/88	4,754,065	Levenson et al.			
	4.	01/24/89	4,800,159	Mullis et al.			
	5.	08/08/95	5,440,013	Kahn			
	6.	11/17/98	5,837,249	Heber-Katz et al.			
FOREIGN PATENT DOCUMENTS							
Examiner Initials	Ref. No.	Date	Document No.	Name	Class Subclass Translation YES NO		
<i>SM</i>	7.	08/01/96	WO 96/23060	The Government of the United States of America	— —		
OTHER DOCUMENTS (including author, title, date, pertinent pages, etc.)							
Examiner Initials	Ref. No.	Title					
<i>SM</i> ↓ <i>V</i>	8.	Altman, J.D. et al., "Phenotypic analysis of antigen-specific T lymphocytes" (1996) <i>Science</i> 274(5284):94-96					
	9.	Bertoni, R. et al., "Human class I supertypes and CTL repertoires extend to chimpanzees" (1998) <i>J. Immunol.</i> 161:4447-4455					
	10.	Boczkowski, D. et al., "Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo" (1996) <i>J. Exp. Med.</i> 184:465-472					
	11.	Bordignon, C. et al., "Retroviral vector-mediated high-efficiency expression of adenosine deaminase (ADA) in hematopoietic long-term cultures of ADA-deficient marrow cells" (1989) <i>PNAS USA</i> 86:6748-6752					
	12.	Carter, B.J., "Adeno-associated virus vectors" (1992) <i>Curr. Op. Biotechnol.</i> 3:533-539					
	13.	Caruso, A. et al., "Flow cytometric analysis of activation markers on stimulated T cells and their correlation with cell proliferation" (1997) <i>Cytometry</i> 27:71-76					
	14.	Correll, P.H. et al., "Production of human glucocerebrosidase in mice after retroviral gene transfer into multipotential hematopoietic progenitor cells" (1989) <i>PNAS USA</i> 86:8912-8916					
	15.	Coulie, P.G., "Human tumour antigens recognized by T cells: new perspectives for anti-cancer vaccines?" (1997) <i>Molec. Med. Today</i> 3:261-268					
	16.	Culver, K. et al., "Lymphocytes as cellular vehicles for gene therapy in mouse and man" (1991) <i>PNAS USA</i> 88:3155-3159					
	17.	Dharanipragada, R. et al., "The absolute configuration of an intermediate in the asymmetric synthesis of unusual amino acids" (1992) <i>Acta. Cryst.</i> C48:1239-1241					
EXAMINER: <i>J. G.</i>		DATE CONSIDERED: <i>12/23/03</i>					
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.							

PTO/SB/08 (2/92)
Sheet 2 of 4


Form PTO-1449		Docket No. 126881209900	Appl. No. 09/870,089 <i>su</i>
INFORMATION DISCLOSURE STATEMENT		Applicant(s) Charles A. NICOLETTE	RECEIVED AUG 14 2001 TC-1700
(use several sheets if necessary)		Filing Date: May 30, 2001	Group Art Unit: Unassigned
<i>su</i>	18.	Dharanipragada, R. et al., "Synthetic linear and cyclic glucagon antagonists" (1993) <i>Int. J. Peptide Protein Res.</i> 42(1):68-77	
	19.	DiMaio, J. et al., "Synthesis of chiral piperazin-2-ones as model peptidomimetics" (1989) <i>J. Chem. Soc. Perkin Trans. 1</i> (9):1687-1689	
	20.	Feltkamp, M.C.W. et al., "Competition inhibition of cytotoxic T-lymphocyte (CTL) lysis, a more sensitive method to identify candidate CTL epitopes than induction of antibody-detected MHC class I stabilization" (1995) <i>Immunol. Lett.</i> 47:1-8	
	21.	Ferguson, et al. "Cell-surface anchoring of proteins via glycosyl-phosphatidylinositol structures" (1988) <i>Ann. Rev. Biochem.</i> 57:285-320	
	22.	Fujihashi, K. et al., "Cytokine-specific ELISPOT assay single cell analysis of IL-2, IL-4 and IL-6 producing cells" (1993) <i>J. Immunol. Meth.</i> 160:181-189	
	23.	Garvey D.S. et al., "3,4-disubstituted γ -lactam rings as conformationally constrained mimics of peptide derivatives containing aspartic acid or norleucine" (1990) <i>J. Org. Chem.</i> 55(3):936-940	
	24.	Hruby, V.J., "Conformational restrictions of biologically active peptides via amino acid side chain groups" (1982) <i>Life Sciences</i> 31:189-199	
	25.	Hruby, V.J. et al. "Emerging approaches in the molecular design of receptor-selective peptide ligands: conformational, topographical and dynamic considerations" (1990) <i>Biochem J.</i> 268:249-262	
	26.	Isakov, N. et al., "ZAP-70 binding specificity to T cell receptor tyrosine-based activation motifs: The tandem SH2 domains of ZAP-70 bind distinct tyrosine-based activation motifs with varying affinity" (1995) <i>J. Exp. Med.</i> 181:375-380	
	27.	Jones, R.C.F. and G.J. Ward, "Amide bond isosteres: imidazolines in pseudopeptide chemistry" (1988) <i>Tetrahedron Lett.</i> 29(31):3853-3856	
	28.	Kahn, M. and S. Bertenshaw, "The incorporation of β -turn prosthetic units into merrifield solid phase peptide synthesis" (1989) <i>Tetrahedron Lett.</i> 30(18):2317-2320	
	29.	Karlsson, S. et al., "Stable gene transfer and tissue-specific expression of a human globin gene using adenoviral vectors" (1986) <i>The EMBO J.</i> 5(9):2377-2385	
	30.	Kawakami, Y. et al., "Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor" (1994) <i>PNAS USA</i> 91(9):3515-3519	
	31.	Kazmierski, W. M. and V.J. Hruby, "Asymmetric synthesis of topographically constrained amino acids: synthesis of the optically pure isomers of α,β -dimethyl-phenylalanine and α,β -dimethyl-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid" (1991) <i>Tetrahedron Lett.</i> 32(41):5769-5772	
	32.	Kazmierski, W.M. et al., "Topographic design of peptide neurotransmitters and hormones on stable backbone templates: relation of conformation and dynamics to bioactivity" (1991) <i>J. Am. Chem. Soc.</i> 113:2275-2283	
	33.	Kemp, D.S. and P.E. McNamara, "Conformationally restricted cyclic nonapeptides derived from L-cysteine and LL-3-amino-2-piperidone-6-carboxylic acid (LL-Acp), a potent β -turn-inducing dipeptide analogue" (1985) <i>J. Org. Chem.</i> 50:5834-5838	
	34.	Kemp, D.S. and B.R. Bowen, "Conformational analysis of peptide-functionalized diacylaminoepindolidiones ^1H NMR evidence for β -sheet formation" (1988) <i>Tetrahedron Lett.</i> 29(40):5081-5082	
<i>V</i>	35.	Kemp, D.S. and W.E. Stites, "A convenient preparation of derivatives of 3(S)-amino-10(R)-carboxy-1, 6-diaza-cyclodeca-2, 7-dione The dilactam of L- α , γ -diaminobutyric acid and D-glutamic acid: A β -turn template" (1988) <i>Tetrahedron Lett.</i> 29(40):5057-5060	

EXAMINER:


DATE CONSIDERED:

12/23/03

EXAMINER: Initial if citation considered whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

PTO/SB/08 (2/92)
Sheet 3 of 4RECEIVED
AUG 14 2001
TC 1700

Form PTO-1449		Docket No. 126881209900	Appl. No. 09/876,088
INFORMATION DISCLOSURE STATEMENT		Applicant(s) Charles A. NICOLETTE	
(use several sheets if necessary)		Filing Date: May 30, 2001	Group Art Unit: Unassigned
36.	Kemp, D.S. and T.P. Curran, "(2, 5S, 8S, 11S)-1-acetyl-1, 4-diaza-3-keto-5-carboxy-10-thia-tricyclo-[2.8.0 ^{4,8}]-ridecane, 1 the preferred conformation of 1 (1= α temp-OH) and its peptide conjugates α temp-L-(Ala) _n -OR (n=1 to 4) and α -temp -L-Ala-L-Phe-Lys(ϵ Boc)-L-Lys(ϵ -Boc)-NHMe studies of templates for α -helix formation" (1988) <i>Tetrahedron Lett.</i> 29(39):4935-4938		
37.	Kemp, D.S. and J.S. Carter, "Amino acid derivatives that stabilize secondary structures of polypeptides. 4. Practical synthesis of 4-(alkylamino)-3-cyano-6-azabicyclo[3.2.1]oct-3-enes (ben derivatives) as γ -turn templates" (1989) <i>J. Org. Chem.</i> 54:109-115		
38.	McGrory, W.J. et al., "Short communications: A simple technique for the rescue of early region I mutation into infectious human adenovirus type 5" (1988) <i>Virology</i> 163:614-617		
39.	Merrifield, R.B., "New approaches to the chemical synthesis of peptides" (1967) <i>Recent Progress in Hormone Res.</i> 23:451-482		
40.	Miyake, A. et al., "Synthesis and angiotensin converting enzyme inhibitory activity of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid derivatives" (1984) <i>J. Takeda Res. Labs.</i> 43(3/4):53-76		
41.	Mosier, D.E. et al., "Resistance to human immunodeficiency virus 1 infection of SCID mice reconstituted with peripheral blood leukocytes from donors vaccinated with vaccinia gp160 and recombinant gp160" (1993) <i>PNAS. USA</i> 90:2443-2447		
42.	Muzyczka, "Use of adeno-associated virus as a general transduction vector for mammalian cells" (1992) <i>Curr. Top. Microbiol. Immunol.</i> 158:97-129		
43.	Nagai, U. and K. Sato, "Synthesis of a bicyclic dipeptide with the shape of β -turn central part" (1985) <i>Tetrahedron Lett.</i> 26(5):647-650		
44.	Nair, S. et al., "Soluble proteins delivered to dendritic cells via pH-sensitive liposomes induce primary cytotoxic T lymphocyte responses in vitro" (1992) <i>J. Exp. Med.</i> 175:609-612		
45.	Olson, G.L. et al., "Design and synthesis of a protein β -turn mimetic" (1990) <i>J. Am. Chem. Soc.</i> 112:323-333		
46.	Paglia, P. et al., "Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo" (1996) <i>J. Exp. Med.</i> 183:317-322		
47.	Pardoll, D.M., "Cancer vaccines" (1998) <i>Nature Med.</i> 4(5 Suppl.):525-531		
48.	Parker, et al., "Sequence motifs important for peptide binding to the human MHC class I molecule, HLA-A2" (1992) <i>J. Immunol.</i> 149(11):3580-3587		
49.	Parker, K.C. et al. (1995) "Peptide Binding to MHC Class I Molecules: Implications for Antigenic Peptide Prediction" <i>Immunol. Res.</i> 14:34-57		
50.	Parkhurst, M.R. et al., "Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues" (1996) <i>J. Immunol.</i> 157:2539-2548		
51.	al-Ramadi, B.K. et al., "Lack of strict correlation of functional sensitization with the apparent affinity of MHC/peptide complexes for the TCR" (1992) <i>J. Immunol.</i> 155(2):662-673		
52.	Rill, D.R. et al., "An approach for the analysis of relapse and marrow reconstitution after autologous marrow transplantation using retrovirus-mediated gene transfer" (1992) <i>Blood</i> 79(10):2694-2700		
53.	Rouse, R.J.D. et al., "Induction in vitro of primary cytotoxic T-lymphocyte responses with DNA encoding herpes simplex virus proteins" (1994) <i>J. Virol.</i> 68(9):5685-5689		
54.	Salazar, E. et al., "Agonist peptide from a cytotoxic T-lymphocyte epitope of human carcinoembryonic antigen stimulates production of TC1-type cytokines and increases tyrosine phosphorylation more efficiently than cognate peptide" (2000) <i>Int. J. Cancer</i> 85:829-838		
55.	Samanen, J. et al., "5,5-dimethylthiazolidine-4-carboxylic acid (DTC) as a proline analog with restricted		
EXAMINER: <i>[Signature]</i>		DATE CONSIDERED: 12/23/03	
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.			

PTO/SB/08 (2/92)
Sheet 4 of 4RECEIVED
AUG 14 2001
TC 1700

Form PTO-1449		Docket No. 126881209900	Appl. No. 09/870,088
INFORMATION DISCLOSURE STATEMENT		Applicant(s) Charles A. NICOLETTE	
(use several sheets if necessary)		Filing Date: May 30, 2001	Group Art Unit: Unassigned
		conformation" (1990) <i>Int. J. Peptide Protein Res.</i> 35:501-509	
56.	Schlesinger, S. and T.W. Dubensky, Jr., "Alphavirus vectors for gene expression and vaccines" (1999) <i>Curr Opin Biotechnol.</i> 10(5):434-439		
57.	Sette, A. et al., "The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes" (1994) <i>J. Immunol.</i> 153(12):5586-5592		
58.	Shirai, M. et al., "CTL responses of HLA-A2.1-transgenic mice specific for hepatitis C viral peptides predict epitopes for CTL of humans carrying HLA-A2.1" (1995) <i>J. Immunol.</i> 154:2733-2742		
59.	Stuber, G. et al., "HLA-A0201 and HLA-B7 binding peptides in the EBV-encoded EBNA-1, EBNA-2 and BZLF-1 proteins detected in the MHC class 1 stabilization assay. Low proportion of binding motifs for several HLA class 1 alleles in EBNA-1" (1995) <i>Int. Immunol.</i> 7(4):653-663		
60.	Tan, L. et al., "An improved assembly assay for peptide binding to HLA-B*2705 and H-2K*class I MHC molecules" (1997) <i>J. Immunol. Meth.</i> 209(1):25-36		
61.	Tanguay, S. and J.J. Killian, "Direct comparison of ELISPOT and ELISA-based assays for detection of individual cytokine-secreting cells" (1994) <i>Lymphokine Cytokine Res.</i> 13(4):259-263		
62.	Valmori, D. et al., "Induction of potent antitumor CTL responses by recombinant vaccinia encoding a melan-A peptide analogue" (2000) <i>J. Immunol.</i> 164(2):1125-1131		
63.	van der Burg, S.H. et al., "Immunogenicity of peptides bound to MHC class I molecules depends on the MHC-peptide complex stability" (1996) <i>J. Immunol.</i> 156:3308-3314		
64.	Ware, C.F. et al., "Recognition of HLA-A2 mutant and variant target cells by an HLA-A2 allospecific human cytotoxic T lymphocyte line" (1983) <i>J. Immunol.</i> 131(3):1312-1317		
65.	Wilchek, M. and E.A. Bayer, "The avidin-biotin complex in bioanalytical applications" (1988) <i>Anal. Biochem.</i> 171:1-32		
66.	Ying, H. et al., "Cancer therapy using a self-replicating RNA vaccine" (1999) <i>Nat. Med.</i> 5(7):823-827		
67.	Zabrocki, J. et al., "Conformational mimicry. 1. 1,5-disubstituted tetrazole ring as a surrogate for the cis amide bond" (1988) <i>J. Am. Chem. Sci.</i> 110:5875-5880		
68.	Zechel, C. et al., "Synthetic glucagon antagonists and partial agonists" (1991) <i>Int. J. Pep. Protein Res.</i> 38(2):131-138		
69.	Zuegel, et al., "Termination of peripheral tolerance to a T cell epitope by heteroclitic antigen analogues" (1998) <i>J. Immunol.</i> 161(4):1705-1709		
70.	Zweerink, H.J. et al., "Presentation of endogenous peptides to MHC class I-restricted cytotoxic T lymphocytes in transport deletion mutant T2 cells" (1993) <i>J. Immunol.</i> 150(5):1763-1771		

EXAMINER:

DATE CONSIDERED: 12/23/03

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

PTO/SB/08 (2/92)
Sheet 1 of 1

Form PTO-1449

EXAMINER: _____ **DATE CONSIDERED:** 18/2/03

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.